FDA Approves TherOx’s SuperSaturated Oxygen Heart Attack Therapy
Clinical trials have shown that SuperSaturated Oxygen Therapy (SSO2 Therapy) reduces the size of myocardial infarcts in the regions of the heart-muscle perfused by the patient’s left anterior descending coronary artery immediately following stenting.
You may also be interested in...
Just months after receiving USA FDA approval for its SuperSaturated Oxygen (SSO2) Therapy for heart-attack treatment, Californian company TherOx has been acquired by Zoll Medical for an undisclosed sum.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved TherOx’s Supersaturated Oxygen System. PharmaEngine/Nanobiotix said its Hensify NBTXR3 nano-particles received the CE mark and plans to market it in 27 European countries for treating locally advanced soft tissue sarcoma.
When it comes to treating acute heart attack patients, primary percutaneous coronary intervention (PPCI) remains the gold standard of care. And while this life-saving procedure restores blood flow through the coronary artery, perfusion in all areas of the heart may not occur. In this article, we'll highlight three innovative medtech companies that have developed very different solutions to try to improve upon the current standard of care and hear perspectives from interventional cardiologists.